Literature DB >> 20878263

Theophylline for bradycardia secondary to cervical spinal cord injury.

Farid Sadaka1, Soophia Khan Naydenov, John J Ponzillo.   

Abstract

BACKGROUND: Spinal cord injury (SCI) is a devastating disease process that can occur as a consequence of motor vehicle collisions, falls, or other traumatic injuries. Persistent bradycardia was found to be universally present in all high cervical SCI patients. Limited data exists to suggest the most effective therapy for the bradycardia associated with high cervical SCI. Treatment includes atropine, epinephrine, dopamine, and even implantable cardiac pacemakers, all of which have their risks and side effects. There are no prospective studies to evaluate methylxanthines for the treatment of bradycardia secondary to cervical SCI.
METHODS: We report on four patients in whom Theophylline was successfully used enterally as a second line agent to treat bradycardia secondary to cervical SCI. We also reported on two patients in whom Theophylline was successfully used as a first line agent. Bradycardia resolved in all patients
RESULTS: Theophylline levels were below toxic levels in all of the patients and no side effects from theophylline were observed.
CONCLUSIONS: Theophylline's use via enteral route can successfully and safely treat SCI-related bradycardia, and may help avoid the long term use of inotropic and chronotropic infusions and pacemakers and their associated risks and complications. We strongly recommend further studies to establish the role of this agent as a first line therapy in this specific patient population. Optimal dosing and duration of therapy will also need to be established.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20878263     DOI: 10.1007/s12028-010-9454-y

Source DB:  PubMed          Journal:  Neurocrit Care        ISSN: 1541-6933            Impact factor:   3.210


  9 in total

1.  The use of small-dose theophylline for the treatment of bradycardia in patients with spinal cord injury.

Authors:  Sebastian Schulz-Stübner
Journal:  Anesth Analg       Date:  2005-12       Impact factor: 5.108

2.  Characteristics of patients with cervical spinal injury requiring permanent pacemaker implantation.

Authors:  Andres F Ruiz-Arango; Vincent J B Robinson; Gyanendra K Sharma
Journal:  Cardiol Rev       Date:  2006 Jul-Aug       Impact factor: 2.644

3.  Cardiac pacemaker in high spinal cord injury.

Authors:  I S Gilgoff; S L Ward; A R Hohn
Journal:  Arch Phys Med Rehabil       Date:  1991-07       Impact factor: 3.966

4.  Sequential use of aminophylline and theophylline for the treatment of atropine-resistant bradycardia after spinal cord injury: a case report.

Authors:  Tomohiro Sakamoto; Tsuneaki Sadanaga; Tomoki Okazaki
Journal:  J Cardiol       Date:  2007-02       Impact factor: 3.159

Review 5.  Optimal drug therapy and therapeutic drug monitoring after spinal cord injury: a population-specific approach.

Authors:  J L Segal; M S Pathak
Journal:  Am J Ther       Date:  2001 Nov-Dec       Impact factor: 2.688

6.  Efficacy of aminophylline for treatment of recurrent symptomatic bradycardia after spinal cord injury.

Authors:  Craig B Whitman; Walter S Schroeder; Peter J Ploch; Krishnan Raghavendran
Journal:  Pharmacotherapy       Date:  2008-01       Impact factor: 4.705

7.  Cardiovascular abnormalities accompanying acute spinal cord injury in humans: incidence, time course and severity.

Authors:  K G Lehmann; J G Lane; J M Piepmeier; W P Batsford
Journal:  J Am Coll Cardiol       Date:  1987-07       Impact factor: 24.094

8.  Use of aminophylline in the treatment of severe symptomatic bradycardia resistant to atropine.

Authors:  Venkat R Pasnoori; Massoud A Leesar
Journal:  Cardiol Rev       Date:  2004 Mar-Apr       Impact factor: 2.644

9.  Aminophylline for the treatment of symptomatic bradycardia and asystole secondary to cervical spine injury.

Authors:  Kyle A Weant; Michaux Kilpatrick; Sivakumar Jaikumar
Journal:  Neurocrit Care       Date:  2007       Impact factor: 3.210

  9 in total
  4 in total

1.  Oral albuterol to treat symptomatic bradycardia in acute spinal cord injury.

Authors:  Amber Rollstin; Michael C Carey; Gloria Doherty; Isaac Tawil; Jonathan Marinaro
Journal:  Intern Emerg Med       Date:  2015-10-05       Impact factor: 3.397

Review 2.  Pediatric Anti-N-Methyl-d-Aspartate Receptor Encephalitis: A Review with Pooled Analysis and Critical Care Emphasis.

Authors:  Kenneth E Remy; Jason W Custer; Joshua Cappell; Cortney B Foster; Nan A Garber; L Kyle Walker; Liliana Simon; Dayanand Bagdure
Journal:  Front Pediatr       Date:  2017-11-24       Impact factor: 3.418

3.  Management of Hypotension and Bradycardia Caused By Spinal Cord Injury. The Usefulness of Midodrine and Methylxanthines.

Authors:  Mojtaba Mojtahedzadeh; Hamidreza Taghvaye-Masoumi; Atabak Najafi; Mehrnoush Dianatkhah; Hamidreza Sharifnia; Maryam Shahrokhi
Journal:  Iran J Pharm Res       Date:  2019       Impact factor: 1.696

Review 4.  Neurocritical care for Anti-NMDA receptor encephalitis.

Authors:  Kuang-Lin Lin; Jann-Jim Lin
Journal:  Biomed J       Date:  2020-04-21       Impact factor: 4.910

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.